中国合理用药探索2025，Vol.22Issue(3)：29-34,6.DOI:10.3969/j.issn.2096-3327.2025.03.006
德谷门冬双胰岛素对比4针胰岛素治疗2型糖尿病患者的疗效观察
Efficacy of Insulin Degludec/Aspart Compared to Four-Dose Insulin in Patients with Type 2 Diabetes Mellitus
摘要
Abstract
Objective:To investigate the effect of twice-daily insulin degludec/aspart(IDegAsp)versus traditional four-dose insulin regimen on glycemia control in patients with type 2 diabetes mellitus.Methods:A retrospective analysis was conducted,in which 82 patients treated with the traditional four-dose insulin regimen in the Endocrinology Department of a hospital from July 2020 to March 2024 were assigned to the control group,and 103 patients treated with IDegAsp in the same department from July 2022 to March 2024 were assigned to the observation group.Both groups wore a continuous glucose monitoring system for 14 days.The fasting plasma glucose(FPG),2 hour postprandial blood glucose(2hPG),and glycosylated haemoglobin were measured after 12 weeks of treatment.Results:After 2 weeks of treatment,the time in range(TIR)in the observation group was longer than that in the control group.The largest amplitude of glycemic excursion(LAGE)and standard deviation(SD)of glucose in the observation group were lower than those in the control group(P<0.05),and the mean amplitude of glucose excursions(MAGE)and coefficient of variation(CV)in the observation group were lower than those in the control group(P<0.01).After 12 weeks of treatment,the FPG of the observation group is significantly higher than that of the control group(P<0.05).There was no statistically significant difference in the changes of 2hPG and HbA1c(P>0.05).Conclusion:The clinical efficacy of IDegAsp was comparable to that of the four-dose insulin regimen.However,the twice-daily IDegAsp treatment group demonstrated superior performance in reducing glycemic variability,along with a lower incidence of hypoglycaemia and fewer injections,thereby alleviating the discomfort associated with needle pricks and improving patient compliance.IDegAsp has the potential to become a new treatment option for patients with type 2 diabetes mellitus who exhibit inadequate response to oral antidiabetic agents or initial insulin therapy.关键词
2型糖尿病/强化治疗/德谷门冬双胰岛素/持续葡萄糖监测/门冬胰岛素注射液Key words
type 2 diabetes mellitus/intensive treatment/insulin degludec/aspart/continuous glucose monitoring/insulin aspart injection分类
医药卫生引用本文复制引用
郑桂梅,梁焯茹,廖志海,廖镜波,程小桂,曹伟灵..德谷门冬双胰岛素对比4针胰岛素治疗2型糖尿病患者的疗效观察[J].中国合理用药探索,2025,22(3):29-34,6.基金项目
深圳市罗湖区软科学研究计划项目(LX20211003,LX202202112) （LX20211003,LX202202112）
深圳市罗湖区人民医院(LCYJ202203) （LCYJ202203）
中国药科大学王广基院士精准药学团队(SZSM202301035) （SZSM202301035）
